Patents by Inventor Ramesh Baliga

Ramesh Baliga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
    Patent number: 10689449
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 23, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Beatrice Tien-Yi Wang, Max A. Schwarzer, Bruce Alan Keyt, Ramesh Baliga
  • MODIFIED J-CHAIN
    Publication number: 20200190190
    Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
    Type: Application
    Filed: February 27, 2020
    Publication date: June 18, 2020
    Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
  • Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
    Patent number: 10669347
    Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 2, 2020
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Christopher D. Thanos, Leslie McEvoy, Gang Yin, Kalyani Penta, Ramesh Baliga, Sunil Bajad, Sonia Pollitt, Chris Murray, Alex Steiner, Avinash Gill
  • Binding molecules with modified J-chain
    Patent number: 10618978
    Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an AD-ME-modulating moiety, and their uses.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 14, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
  • Multi-valent hepatitis B virus antigen binding molecules and uses thereof
    Patent number: 10604559
    Abstract: This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: March 31, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
  • Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
    Patent number: 10501558
    Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: December 10, 2019
    Assignee: Sutro Biopharma, Inc.
    Inventors: Christopher D. Thanos, Leslie McEvoy, Gang Yin, Kalyani Penta, Ramesh Baliga, Sunil Bajad, Sonia Pollitt, Chris Murray, Alex Steiner, Avinash Gill
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20190338031
    Abstract: Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.
    Type: Application
    Filed: May 9, 2017
    Publication date: November 7, 2019
    Inventors: Bruce KEYT, Leonard George PRESTA, Ramesh BALIGA
  • MULTIMERIC CD137/4-1BB BINDING MOLECULES AND USES THEREOF
    Publication number: 20190338040
    Abstract: This disclosure provides dimeric, pentameric, and hexameric CD137/4-1BB agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 7, 2019
    Inventors: Bruce Alan Keyt, Ramesh BALIGA, Beatrice Tien-Yi Wang
  • MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF
    Publication number: 20190338041
    Abstract: This disclosure provides dimeric, pentameric, and hexameric CD40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 7, 2019
    Inventors: Ramesh BALIGA, Beatrice Tien-Yi Wang, Dalya Rivka ROSNER, Bruce Alan Keyt
  • MULTIMERIC GITR BINDING MOLECULES AND USES THEREOF
    Publication number: 20190330360
    Abstract: This disclosure provides dimeric, pentameric, and hexameric GITR agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: July 20, 2017
    Publication date: October 31, 2019
    Inventors: Beatrice Tien-Yi WANG, Bruce Alan Keyt, Ramesh BALIGA
  • MULTIMERIC OX40 BINDING MOLECULES AND USES THEREOF
    Publication number: 20190330374
    Abstract: This disclosure provides dimeric, pentameric, and hexameric OX40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: July 20, 2017
    Publication date: October 31, 2019
    Inventors: Beatrice Tien-Yi WANG, Dalya Rivka Rosner, Ramesh BALIGA, Bruce Alan Keyt
  • Modified J-chain
    Patent number: 10400038
    Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: September 3, 2019
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
  • BINDING MOLECULES WITH MODIFIED J-CHAIN
    Publication number: 20190185570
    Abstract: The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.
    Type: Application
    Filed: September 30, 2016
    Publication date: June 20, 2019
    Inventors: Bruce A. Keyt, Leonard George Presta, Ramesh Baliga
  • CD20 BINDING MOLECULES AND USES THEREOF
    Publication number: 20190100597
    Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
    Type: Application
    Filed: March 4, 2015
    Publication date: April 4, 2019
    Applicant: IGM Biosciences, Inc.
    Inventors: Bruce Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
  • MODIFIED J-CHAIN
    Publication number: 20190002566
    Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 3, 2019
    Inventors: Bruce Alan Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
  • BINDING MOLECULES WITH MODIFIED J-CHAIN
    Publication number: 20180265596
    Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an AD-ME-modulating moiety, and their uses.
    Type: Application
    Filed: September 30, 2016
    Publication date: September 20, 2018
    Inventors: Bruce A. Keyt, Leonard George Presta, Ramesh Baliga
  • MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF
    Publication number: 20180118814
    Abstract: This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Application
    Filed: March 25, 2016
    Publication date: May 3, 2018
    Inventors: Stephen F. Carroll, Ramesh Baliga, Dean NG, Bruce A. Keyt
  • Modified J-chain
    Patent number: 9951134
    Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies, comprising the same, and their uses.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 24, 2018
    Assignee: IGM BIOSCIENCES A/S
    Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
  • Tumor necrosis factor (TNF) superfamily receptor IgM antibodies and uses thereof
    Patent number: 9938347
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 10, 2018
    Assignee: IGM BIOSCIENCES A/S
    Inventors: Beatrice Tien-Yi Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga
  • ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE
    Publication number: 20180036425
    Abstract: Provided herein are antibodies comprising multiple non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 8, 2018
    Inventors: Christopher D. Thanos, Ramesh Baliga, Kalyani Penta, Avinash Gill, Gang Yin, Erik Zimmerman